Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.
复制标题
DOI：
10.1007/s10637-007-9076-1
复制
发表时间：
2007-12
影响因子：
3.4
通讯作者：
Dagnelie, Pieter C.
中科院分区：
文献类型：
--
作者：
Beijer, Sandra;Gielisse, Eric A. R.;Hupperets, Pierre S.;van den Borne, Ben E. E. M.;van den Beuken-van Everdingen, Marieke;Nijziel, Marten R.;van Henten, Arjen M. J.;Dagnelie, Pieter C.
本研究的目的是调查在家庭中给予晚期癌症患者5′-三磷酸腺苷（ATP）的安全性。纳入的癌症患者的医疗选择仅限于支持性护理，预期寿命不到6个月，世界卫生组织体能状态1或2，并且患有以下至少一种主诉：疲劳，厌食或体重减轻>5%。根据美国国家癌症研究所（NCI）常见毒性标准，在标准表格上系统登记副作用。51例患者共接受了266次静脉ATP输注。其中，11次输注（4%）以20 μg kg−1 min−1的最低剂量给药，85次输注（32%）以25-40 μg kg−1 min−1给药，170次输注（64%）以45-50 μg kg−1 min−1的最高剂量给药。大多数ATP输注（63%）没有副作用。呼吸困难是最常见的副作用（14%的输注），其次是胸部不适（12%）和深呼吸的冲动（11%）。在任何输注中均未发生心肌缺血症状。所有副作用均为一过性，并在降低ATP输注速率后数分钟内消退。副作用最常见于心脏疾病。我们的结论是，ATP的最大剂量为50 μg kg−1 min−1，可以安全地在家庭环境中给予晚期前癌症患者。
The aim of the study was to investigate the safety of adenosine 5′-triphosphate (ATP) administration at home in pre-terminal cancer patients. Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a World Health Organization performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, anorexia or weight loss >5% over the previous 6 months. Side effects were registered systematically on a standard form according to the National Cancer Institute (NCI) Common Toxicity Criteria. Fifty-one patients received a total of 266 intravenous ATP infusions. Of these, 11 infusions (4%) were given at the lowest dose of 20 μg kg−1 min−1, 85 infusions (32%) at 25–40 μg kg−1 min−1, and 170 (64%) at the highest dose of 45–50 μg kg−1 min−1 ATP. The majority of ATP infusions (63%) were without side effects. Dyspnea was the most common side effect (14% of infusions), followed by chest discomfort (12%) and the urge to take a deep breath (11%). No symptoms of cardiac ischemia occurred in any of the infusions. All side effects were transient and resolved within minutes after lowering the ATP infusion rate. Side effects were most frequent in the presence of cardiac disorders. We conclude that ATP at a maximum dose of 50 μg kg−1 min−1 can be safely administered in the home setting in patients with pre-terminal cancer.
登录
查看更多内容
影响因子：
2.8
作者：
Fukuda, Kenn-ichi;Hayashida, Masakazu;Kaneko, Yuzuru
通讯作者：
Kaneko, Yuzuru
影响因子：
3.4
作者：
Haskell, CM;Mendoza, E;Figlin, RA
通讯作者：
Figlin, RA
影响因子：
45.3
作者：
Agteresch, HJ;Rietveld, T;Dagnelie, PC
通讯作者：
Dagnelie, PC
影响因子：
39.2
作者：
DIMARCO, JP;MILES, W;GOVIER, WC
通讯作者：
GOVIER, WC
影响因子：
39.3
作者：
DOMANOVITS, H;LASKE, H;LAGGNER, AN
通讯作者：
LAGGNER, AN